BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, February 5, 2026
See today's BioWorld Asia
Home
» FDA clears Chengdian (Suzhou) Biopharmaceutical’s IND for CD-001
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
FDA clears Chengdian (Suzhou) Biopharmaceutical’s IND for CD-001
Sep. 24, 2024
Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001.
BioWorld Asia
Regulatory
Cancer
Antibody
Immuno-oncology
FDA
IND
